oxurion
nv
business
update
oxurion
nv
business
update
progressing
clinical
development
next
generation
diabetic
macular
edema
dme
therapies
beyond
positive
data
phase
study
evaluating
integrin
antagonist
treatment
dme
first
patient
dosed
phase
kalahari
study
evaluating
potent
plasma
kallikrein
inhibitor
treatment
dme
total
cash
investments
million
june
highlights
focused
developing
diabetic
macular
edema
dme
franchise
based
novel
therapeutics
potential
improve
vision
dme
patients
dme
franchise
based
two
innovative
drug
candidates
different
complementary
modes
action
first
patient
dosed
phase
kalahari
study
evaluating
multiple
injections
potent
plasma
kallikrein
inhibitor
treatment
dme
september
positive
data
phase
study
evaluating
integrin
antagonist
treatment
dme
announced
january
preparations
phase
study
dme
progressing
planned
study
expected
start
august
oxurion
appointed
grace
chang
chief
medical
officer
lead
company
clinical
programs
financial
end
june
oxurion
cash
cash
equivalents
investments
million
compares
million
end
december
conference
call
scheduled
september
pm
cet
details
end
release
leuven
belgium
september
pm
cet
oxurion
nv
euronext
brussels
oxur
biopharmaceutical
company
developing
next
generation
ophthalmic
therapies
focus
diabetic
macular
edema
dme
today
issues
business
financial
update
period
ending
june
oxurion
focused
developing
industry
leading
dme
franchise
based
novel
therapies
designed
potentially
provide
improved
visual
outcomes
dme
patients
company
progressing
pipeline
innovative
clinical
drug
candidates
treating
dme
dme
significant
global
healthcare
problem
major
cause
vision
loss
diabetic
patients
worldwide
oxurion
clinical
development
pipeline
consists
two
novel
products
different
complimentary
modes
action
potent
plasma
kallikrein
inhibitor
potential
become
treatment
choice
dme
patients
respond
therapy
potent
plasma
kallikrein
inhibitor
potential
become
treatment
choice
dme
patients
respond
therapy
best
class
small
molecule
integrin
antagonist
developed
treat
dme
possibility
become
standard
care
dme
patients
patrik
de
haes
ceo
oxurion
said
made
significant
progress
developing
dme
franchise
first
half
following
positive
phase
results
january
announced
positive
highly
promising
phase
results
showing
novel
integrin
antagonist
potential
deliver
improved
visual
outcomes
broad
population
dme
patients
compared
current
standard
care
recently
started
phase
study
patients
dme
study
first
select
optimal
dose
compare
aflibercept
terms
improvements
best
corrected
visual
acuity
phase
data
designed
support
plans
position
treatment
choice
large
number
dme
patients
response
therapy
successfully
developing
two
novel
complimentary
drug
candidates
could
offer
improved
therapeutic
options
beyond
believe
positioned
build
industry
leading
dme
franchise
confident
creating
franchise
deliver
significant
benefits
nearly
dme
patients
globally
parallel
generate
attractive
returns
diabetic
macular
edema
oxurion
key
focus
diabetic
macular
edema
dme
complication
diabetes
caused
fluid
accumulation
macula
central
part
retina
due
leaking
blood
vessels
leading
swelling
macular
area
due
increased
permeability
vessels
dme
result
another
complication
diabetes
called
diabetic
retinopathy
dr
blood
vessels
eye
damaged
allowing
fluid
escape
dr
presence
characteristic
evolution
typical
retinal
microvascular
lesions
individual
diabetes
dr
chronic
progressive
disease
leading
cause
vision
loss
adults
years
dme
consequence
dr
occur
stage
development
one
three
people
living
diabetes
develop
form
dr
lifetime
third
form
disease
dme
dr
dme
growing
public
health
concern
due
rapid
growth
number
people
diabetes
globally
estimated
million
people
diagnosed
diabetes
united
states
us
european
top
five
countries
france
germany
italy
spain
united
kingdom
japan
undiagnosed
population
included
estimated
number
people
diabetes
countries
increases
million
people
prevalence
dme
estimated
million
people
us
japan
market
value
dme
treatments
markets
estimated
approximately
billion
market
dme
therapies
dominated
current
standard
care
however
shown
deliver
results
significant
portion
patient
population
around
dme
patients
unsatisfactory
early
visual
response
therapy
many
cases
fail
achieve
clinically
meaningful
visual
improvement
oxurion
focused
solving
unmet
medical
needs
dme
oxurion
emerging
dme
franchise
general
treatment
dme
centered
around
therapies
however
despite
significant
success
always
need
physicians
patients
improved
therapies
treatment
capabilities
dme
patients
respond
faster
onset
action
better
therapeutic
effect
terms
visual
function
best
corrected
visual
acuity
bcva
response
rate
proportion
patients
longer
duration
response
allowing
extended
treatment
intervals
improved
convenience
treatment
simpler
dosing
regimen
requirements
driving
development
meet
specific
unmet
needs
market
novel
compounds
could
become
new
standard
care
patients
dme
oxurion
emerging
dme
franchise
based
successful
development
two
novel
therapeutics
different
modes
action
designed
specific
complementary
target
patient
groups
oxurion
confident
able
provide
new
tailored
therapeutic
solutions
deliver
improved
clinical
outcomes
dme
patients
oxurion
dme
pipeline
plasma
kallikrein
inhibitor
treatment
dme
first
patient
treated
phase
study
evaluating
treatment
dme
novel
plasma
kallikrein
inhibitor
developed
potential
new
standard
care
dme
patients
respond
therapy
acts
inhibition
plasma
system
validated
target
dme
phase
study
showed
safe
toxicities
serious
adverse
events
reported
dosages
evaluated
study
delivered
promising
results
relation
efficacy
particularly
improvements
patient
bcva
rapid
onset
action
observed
day
increasing
average
improvement
bcva
letters
day
importantly
activity
maintained
average
improvement
bcva
letters
day
following
single
injection
data
positive
phase
study
presented
several
major
retina
conferences
europe
us
including
european
society
retina
specialists
euretina
paris
retina
society
annual
meeting
london
currently
phase
development
program
kalahari
study
first
part
part
evaluate
dose
levels
patients
dme
select
optimal
dose
compared
current
standard
care
form
aflibercept
eylea
second
part
study
part
b
initial
data
part
expected
novel
drug
candidate
generated
using
bicycle
therapeutics
technology
platform
small
molecule
integrin
antagonist
treatment
dme
positive
phase
results
treatment
dme
phase
program
expected
start
oxurion
developing
integrin
antagonist
preserve
vision
broad
range
patients
dme
topline
data
phase
trial
showed
safe
toxicities
serious
adverse
events
reported
doses
evaluated
study
study
also
looked
efficacy
including
changes
patient
bcva
across
doses
rapid
onset
action
measured
mean
bcva
change
observed
day
increase
letters
improved
letters
month
activity
maintained
mean
bcva
improvement
letters
month
following
single
injection
clear
dose
response
seen
terms
bcva
highest
dose
delivering
mean
bcva
improvement
letters
day
peak
improvement
letters
month
addition
peak
mean
central
subfield
thickness
cst
decrease
µm
observed
day
highest
dose
data
positive
phase
study
presented
leading
retina
expert
bascom
palmer
eye
institute
angiogenesis
exudation
degeneration
meeting
february
miami
us
oxurion
preparing
phase
study
expected
start
appointments
august
oxurion
appointed
grace
chang
chief
medical
officer
effective
august
responsible
leading
company
clinical
programs
oxurion
looks
build
dme
franchise
could
provide
much
improved
therapeutic
solutions
dme
patients
dr
chang
ophthalmologist
practicing
vitreoretinal
surgeon
deep
expertise
ophthalmic
drug
research
development
dr
chang
currently
adjunct
clinical
associate
professor
department
ophthalmology
vitreoretinal
service
university
southern
california
los
angeles
march
oxurion
also
appointed
kathleen
paisley
chief
legal
officer
michaël
dillen
chief
corporate
development
corporate
secretary
kathleen
accomplished
lawyer
years
experience
major
law
firms
practicing
brussels
london
hague
joins
oxurion
ambos
nbgo
partner
nearly
ten
years
kathleen
extensive
experience
international
business
transactions
especially
biotech
tech
sector
regulatory
compliance
eu
competition
law
kathleen
degree
yale
law
school
well
mba
finance
florida
atlantic
university
passed
certified
public
accountancy
exam
michaël
company
secretary
vp
corporate
development
mithra
pharmaceuticals
sa
prior
joining
oxurion
years
legal
experience
including
corporate
development
corporate
counsel
legal
regulatory
company
secretary
activities
pharmaceutical
companies
well
leading
law
firms
previously
chief
legal
officer
terumo
michaël
received
law
degrees
university
antwerp
queen
mary
university
london
business
degree
solvay
brussels
school
jetrea
marketing
authorization
transitioned
inceptua
group
march
oxurion
announced
signing
global
commercial
license
agreement
inceptua
group
inceptua
group
global
pharmaceutical
company
service
partner
spanning
product
lifecycle
clinical
trials
early
access
programs
licensing
commercialization
products
group
offices
europe
us
asia
september
company
received
final
approval
european
commission
official
transfer
marketing
authorization
inceptua
group
means
commercialized
solely
inceptua
basis
allow
oxurion
fully
focus
developing
dme
franchise
oncurious
clinical
activities
progressing
planned
financial
update
first
six
months
oxurion
reported
gross
profit
million
compared
gross
profit
million
period
oxurion
r
expenses
million
first
half
year
period
r
expenses
million
incremental
investments
related
start
phase
clinical
study
evaluating
work
needed
prepare
phase
clinical
study
largely
offset
million
decline
costs
due
halting
clinical
developments
overall
reduction
activities
related
selling
marketing
expenses
amounted
million
compared
million
corresponding
period
decrease
directly
related
discontinuation
commercial
support
general
administrative
expenses
million
compares
million
first
half
first
half
oxurion
reported
net
loss
million
per
share
compared
net
loss
million
period
figure
included
million
remaining
intangible
assets
well
operating
current
loss
million
june
oxurion
million
cash
cash
equivalents
investments
compared
million
end
december
conference
call
english
scheduled
september
cet
bst
webcast
link
conference
call
https
oxurion
teys
participant
telephone
numbers
brussels
belgium
toll
free
standard
international
access
uk
toll
free
usa
toll
free
password
oxurion
replay
call
available
oxurion
website
following
live
event
end
information
please
contact
oxurion
nv
wouter
piepers
global
head
investor
relations
corporate
communications
tel
citigate
dewe
rogerson
david
dible
sylvie
berrebi
frazer
hall
tel
oxurion
oxurion
oxurion
euronext
brussels
oxur
biopharmaceutical
company
developing
next
generation
standard
care
ophthalmic
therapies
designed
better
preserve
vision
patients
diabetic
macular
edema
dme
leading
cause
vision
loss
diabetic
patients
worldwide
oxurion
building
leading
global
franchise
treatment
dme
based
successful
development
two
novel
therapeutics
plasma
kallikrein
inhibitor
developed
potential
new
standard
care
dme
patients
respond
therapy
shown
positive
topline
phase
results
treatment
dme
company
currently
conducting
phase
clinical
trial
evaluating
previously
responded
therapy
developed
conjunction
bicycle
therapeutics
plc
nasdaq
bcyc
integrin
inhibitor
initially
developed
potential
new
standard
care
dme
patients
positive
topline
results
phase
clinical
study
assessing
treatment
dme
announced
january
expected
enter
phase
clinical
trial
mid
optimized
compound
derived
broader
library
integrin
inhibitors
galapagos
nv
euronext
nasdaq
glpg
oxurion
headquartered
leuven
belgium
listed
euronext
brussels
exchange
symbol
oxur
information
available
important
information
statements
certain
statements
press
release
may
considered
statements
based
current
expectations
accordingly
entail
influenced
various
risks
uncertainties
company
therefore
provide
assurance
statements
materialize
assume
obligation
update
revise
statement
whether
result
new
information
future
events
reason
additional
information
concerning
risks
uncertainties
affecting
business
factors
could
cause
actual
results
differ
materially
statement
contained
company
annual
report
press
release
constitute
offer
invitation
sale
purchase
securities
assets
oxurion
jurisdiction
securities
oxurion
may
offered
sold
within
united
states
without
registration
securities
act
amended
compliance
exemption
therefrom
accordance
applicable
state
securities
laws
unaudited
consolidated
statement
profit
loss
euro
period
ended
june
income
sales
income
royalties
cost
sales
gross
profit
research
development
expenses
general
administrative
expenses
selling
expenses
operating
income
impairment
losses
operating
result
finance
income
finance
expense
result
income
tax
taxes
loss
period
attributable
equity
holders
company
interest
result
per
share
basic
earnings
loss
per
share
euro
diluted
earnings
loss
per
share
euro
unaudited
consolidated
statements
comprehensive
income
euro
period
ended
june
loss
period
exchange
differences
translation
foreign
operations
comprehensive
income
net
income
tax
comprehensive
income
reclassified
profit
loss
total
comprehensive
income
period
attributable
equity
holders
company
interest
unaudited
consolidated
statement
financial
position
euro
assets
property
plant
equipment
assets
intangible
assets
assets
tax
credit
assets
inventories
trade
receivables
current
tax
receivables
investments
cash
cash
equivalents
current
assets
total
assets
equity
liabilities
share
capital
share
premium
cumulative
translation
differences
reserves
retained
earnings
equity
attributable
equity
holders
company
interest
total
equity
lease
liabilities
liabilities
trade
payables
lease
liabilities
liabilities
current
liabilities
total
equity
liabilities
unaudited
consolidated
statement
cash
flows
euro
period
ended
june
cash
flows
operating
activities
loss
period
finance
expense
finance
income
depreciation
property
plant
equipment
amortization
impairment
intangible
assets
equity
settled
payment
transactions
decrease
trade
receivables
including
tax
receivables
inventories
decrease
liabilities
net
cash
flows
used
generated
operating
activities
cash
flows
investing
activities
disposal
property
plant
equipment
following
sale
decrease
increase
investments
interest
received
similar
income
purchase
property
plant
equipment
net
cash
flows
used
generated
investing
activities
cash
flows
financing
activities
principal
paid
lease
liabilities
interest
paid
lease
liabilities
paid
interests
net
cash
flows
used
generated
financing
activities
net
change
cash
cash
equivalents
net
cash
cash
equivalents
beginning
period
effect
exchange
rate
fluctuations
net
cash
cash
equivalents
end
period
unaudited
consolidated
statement
changes
equity
share
capital
share
premium
cumulative
translation
differences
reserves
retained
earnings
attributable
equity
holders
company
interest
total
january
loss
period
change
foreign
currency
translation
difference
revaluation
reserve
payment
transactions
june
january
loss
period
change
foreign
currency
translation
difference
revaluation
reserve
payment
transactions
june
attachment
